However, in the other case, the metastatic tumor exhibited identical KRAS mutations to the primary tumor and harbored additional mutations in genes related to the mitogen-activated protein kinase pathway (mitogen-activated protein kinase kinase kinase 13, mesenchymal epithelial transition, and mitogen-activated protein kinase 3). The gene discussed is KRAS; the disease is metastatic neoplasm.